Drugs used in eye disease

Starting people on bevacizumab and switching to aflibercept only when necessary keeps costs down without compromising treatment efficacy for people with diabetic macular edema, shows a randomized trial.

The dual Ang-2 and VEGF-A pathway inhibitor faricimab is noninferior to aflibercept for improving visual acuity in people with diabetic macular edema, and an individualized dosing strategy could help reduce treatment burden, suggest findings from the YOSEMITE and RHINE trials.

Intravitreous aflibercept and vitrectomy with panretinal laser photocoagulation appear to have similar efficacy over 24 weeks when used for the treatment of vitreous hemorrhage from proliferative diabetic retinopathy, researchers report.

Here we provide an overview of the seven Cochrane reviews published in June that covered topics relating to diabetes, including glycemic control for prevention of renal failure, phototherapy for foot ulcers, and anti-vascular endothelial growth factor treatment for diabetic macular edema.

Results of the CLARITY trial suggest that aflibercept treatment may produce better visual outcomes than laser photocoagulation in patients with proliferative diabetic retinopathy.

A substantial proportion of diabetes patients experience improvements in diabetic retinopathy while receiving anti-vascular endothelial growth factor treatment, shows the latest analysis from DRCR.net.